3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide

• ChemBase编号: 292
• 分子式: C16H23BrN2O3
• 平均质量: 371.26942
• 单一同位素质量: 370.08920461
• SMILES: Brc1c(OC)c(C(=O)NC[C@H]2N(CCC2)CC)c(OC)cc1
• Canonical SMILES: CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(c1OC)Br
• InChI: InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
• InChIKey: GUJRSXAPGDDABA-NSHDSACASA-N

名称和登记号

名称

• IUPAC标准名: 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide
• IUPAC传统名: remoxipride
• 别名: Remoxiprida [INN-Spanish]; Remoxipride [Usan:Ban:Inn]; Remoxipridum [INN-Latin]; Romoxipride; Remoxipride; (S)-3-BroMo-N-((1-ethylpyrrolidin-2-yl)Methyl)-2,6-diMethoxybenzaMide

登记号

• CAS号: 80125-14-0
• PubChem SID: 46508689; 160963755
• PubChem CID: 54477

理论计算性质

JChem

• Acid pKa: 13.061707
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): -0.46103975
• LogD (pH = 7.4): 1.3025001
• Log P: 2.3419893
• 摩尔折射率: 90.5612 cm^3
• 极化性: 34.70597 Å^3
• 极化表面积: 50.8 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.94
• LOG S: -3.47
• 溶解度: 1.27e-01 g/l

分子性质

理化性质

• 溶解度: 74 mg/L
• 疏水性(logP): 2.9

产品相关信息

• 纯度: 97%

详细说明

DrugBank - DB00409

• Drug Groups: approved; withdrawn
• Description: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem]
• Indication: Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.
• Pharmacology: Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.
• Affected Organisms: Humans and other mammals
• Biotransformation: No active metabolites
• Absorption: Rapidly absorbed. Absolute bioavailability is 90%.
• Half Life: 4-7 hours
• Protein Binding: 89-98%
• External Links: Wikipedia